Thomas Tan
Private Equity Investor at Lundbeckfonden Ventures
Profile
Thomas Tan is currently working as a Principal at Lundbeckfonden Ventures, Sound Bioventures Management ApS, and Sound Bioventures Management AB.
Previously, he held positions as a Director at Atox Bio Ltd., a Member-Supervisory Board at VarmX BV, a Manager at Huron Consulting Services U.K.
Ltd., and an Engagement Manager at Lifescience Dynamics Ltd.
Mr. Tan obtained a doctorate degree from the University of Oxford in 2010 and a graduate degree from the University of Copenhagen in 2006.
Thomas Tan active positions
Companies | Position | Start |
---|---|---|
Lundbeckfonden Ventures
Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Private Equity Investor | 2020-12-31 |
Sound Bioventures Management ApS | Private Equity Investor | 2022-03-31 |
Sound Bioventures Management AB
Sound Bioventures Management AB Investment ManagersFinance Sound Bioventures Management AB is a venture capital firm founded in 2021 by Casper Breum, Johan Kordel and Bibhash Mukhopadhyay. The firm is headquartered in Malmo, Sweden. | Private Equity Investor | 2021-12-31 |
Former positions of Thomas Tan
Companies | Position | End |
---|---|---|
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Director/Board Member | 2022-04-29 |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Director/Board Member | 2022-04-29 |
Lifescience Dynamics Ltd. | Corporate Officer/Principal | 2021-01-30 |
Huron Consulting Services U.K. Ltd.
Huron Consulting Services U.K. Ltd. Miscellaneous Commercial ServicesCommercial Services Pope Woodhead & Associates Ltd. provides management consultancy services. The company was founded on November 9, 2006 and is headquartered in Saint Ivens, the United Kingdom. | Corporate Officer/Principal | 2020-07-30 |
Training of Thomas Tan
University of Oxford | Doctorate Degree |
University of Copenhagen | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 7 |
---|---|
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
Lundbeckfonden Ventures
Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Finance |
Lifescience Dynamics Ltd. | |
Huron Consulting Services U.K. Ltd.
Huron Consulting Services U.K. Ltd. Miscellaneous Commercial ServicesCommercial Services Pope Woodhead & Associates Ltd. provides management consultancy services. The company was founded on November 9, 2006 and is headquartered in Saint Ivens, the United Kingdom. | Commercial Services |
Sound Bioventures Management ApS | Finance |
Sound Bioventures Management AB
Sound Bioventures Management AB Investment ManagersFinance Sound Bioventures Management AB is a venture capital firm founded in 2021 by Casper Breum, Johan Kordel and Bibhash Mukhopadhyay. The firm is headquartered in Malmo, Sweden. | Finance |
- Stock Market
- Insiders
- Thomas Tan